Moreover, given atherosclerosis as the most prevalent underlying condition, it is unknown whether aggressive lipid lowering therapies with PCSK-9 inhibitors might provide a prognostic benefit in CAE patients with ACS. The gene discussed is PCSK9; the disease is atherosclerosis.